|4.||POEMS Syndrome (Syndrome, POEMS)
|1.||Janz, Siegfried: 17 articles (01/2012 - 02/2002)|
|2.||Anderson, Kenneth C: 10 articles (03/2012 - 09/2002)|
|3.||Kyle, Robert A: 8 articles (07/2014 - 02/2002)|
|4.||Dispenzieri, Angela: 8 articles (07/2014 - 09/2006)|
|5.||Kovalchuk, Alexander L: 8 articles (07/2012 - 02/2002)|
|6.||Chauhan, Dharminder: 8 articles (05/2011 - 11/2002)|
|7.||Rajkumar, S Vincent: 7 articles (07/2014 - 02/2002)|
|8.||Potter, Michael: 7 articles (07/2012 - 02/2002)|
|9.||Hideshima, Teru: 7 articles (03/2012 - 09/2002)|
|10.||Janz, S: 6 articles (01/2015 - 05/2000)|
|1.||Melphalan (Alkeran)FDA LinkGeneric
06/15/1990 - "BALB/c mice cured of large MOPC-315 plasmacytomas by melphalan remain deficient in their spleen T-cell functions. "
01/01/1989 - "Deficiency in immunocompetence of mice cured from large MOPC-315 plasmacytomas by melphalan therapy."
03/01/1988 - "Late immune and haemopoietic functions in plasmacytoma-bearing mice cured by melphalan."
01/01/1987 - "Immune functions and hematopoietic progenitor cell activity in plasmacytoma-bearing mice cured by melphalan."
01/01/1987 - "BALB/c mice cured of a large MOPC-315 or MOPC-104E plasmacytoma following treatment with a low dose (2.5 mg/kg) of melphalan (L-PAM) were resistant to challenge with the other plasmacytoma but to a much lesser extent than to challenge with the autochthonous plasmacytoma. "
|2.||Cyclophosphamide (Cytoxan)FDA LinkGeneric
01/01/1993 - "We show here that in contrast to BALB/c mice bearing a late-stage, large MOPC-315 plasmacytoma, BALB/c mice bearing a late-stage, large RPC-5 plasmacytoma were not cured by cyclophosphamide therapy (15, 50, 100 or 200 mg/kg). "
02/01/1964 - "STUDIES OF MOUSE PLASMA CELL TUMOR AND HUMAN MYELOMA RESPONSIVENESS TO CYCLOPHOSPHAMIDE (CYTOXAN)."
08/01/1988 - "We have analyzed the expression of cyclophosphamide (CY) resistance in somatic cell hybrids of mouse LPC-1/CY-R plasmacytoma and P3-X63-Ag8.653 (Ag8) myeloma cells. "
01/01/1988 - "Effect of low-dose cyclophosphamide therapy on specific and nonspecific T cell-dependent immune responses of spleen cells from mice bearing large MOPC-315 plasmacytomas."
12/01/1985 - "Cellular changes and antitumor responses in the plasmacytoma-bearing mouse following cyclophosphamide treatment."
01/01/2010 - "We present the case of a 47-year-old man with an extremely aggressive extramedullary plasmacytoma of the lung with associated cutaneous lesions, whose disease was accompanied by a significantly decreased number of NK cells (CD56+, CD16+, CD3-) in the peripheral blood, very low NK cell activity levels, and a decreased interleukin-2 production from cultured cells in vitro. "
01/01/2000 - "The results indicate that upregulation of the CD80 molecule expression and enhanced IL-2 production in irradiated X63-m-IL-2 cells was responsible for the higher therapeutic effectiveness of the irradiated plasmacytoma vaccine."
01/01/1999 - "administration of irradiated IL-2-producing plasmacytoma (X63-m-IL-2) vaccine, the levels of IL-2 were substantially higher in the peritoneal fluid than in the serum. "
02/01/1998 - "In vivo adenoviral-mediated gene transfer of interleukin-2 in cutaneous plasmacytoma."
01/01/1998 - "Two murine plasma cell tumor lines, S107 and X24, were infected with a retroviral vector expressing the human IL-2 gene, and the antitumor potential of IL-2-expressing infectants was characterized in syngeneic BALB/c and BALB/c nu/nu mice. "
|4.||bortezomib (Velcade)FDA Link
02/01/2009 - "It has also been reported that bortezomib is effective for solitary extramedullary plasmacytoma (EMP). "
08/01/2006 - "This report lends support to the efficacy of bortezomib in the treatment of plasmacytoma and describes the safe use of bortezomib despite hepatic upset."
05/01/2009 - "These results lend support to the efficacy of bortezomib in the treatment of plasmacytoma. "
05/01/2008 - "Efficacy of Bortezomib followed by local irradiation in two patients with extramedullary plasmacytomas."
01/01/2015 - "To investigate the in vivo effectiveness of CAPE and bortezomib, an experimental plasmacytoma model was induced in BALB/c mice. "
04/01/2011 - "In this study, we produced polyclonal rabbit anti-murine plasmacytoma cell immunoglobulin (PAb) by immunizing rabbits with the murine plasmacytoma cell line MPC-11. "
06/01/2015 - "Plasmacytoma classified into solitary plasmacytoma of bone (SPB) and extramedullary plasmacytoma (EMP) is characterized by infiltrate of plasma cells of diverse maturity and by their monoclonal immunoglobulin products. "
01/01/2014 - "Plasma cell tumors are characterized by a monoclonal proliferation of immunoglobulin-secreting plasma cells. "
01/01/2013 - "Plasmacytoma cells infiltrated multiple loci in the bone marrow, spleen and liver; secreted immunoglobulins; and caused glomerular damage. "
01/01/2013 - "Pathologic analysis revealed a malignant neoplasia described as a plasmocytoma (solitary myeloma) that produces immunoglobulin's kappa light chain. "
01/01/2001 - "Concomitantly, resistant C57BL/6 mice, from which both gene products of the Cdkn2a gene have been eliminated, developed pristane-induced plasma cell tumors over a shorter latency period than the traditionally susceptible BALB/cAn strain. "
10/01/2009 - "Our study was initiated to identify the modifier gene(s) encoded by the Pctm locus, in which mouse B-cell plasmacytomas induced by pristane are associated with heterozygosity of Chr 1 genes near the Ifi200 cluster. "
01/01/1990 - "The studies showed that APECs from mice exposed to treatment with pristane were able to stimulate growth of both TEPC-15f and MP-26 plasmacytoma. "
03/01/2009 - "Here we review these advances and discuss the usage of pristane-induced mouse plasmacytomas as a tool to investigate the origin of Igh-cMyc translocations and B-cell tumorigenesis."
03/15/2007 - "Plasmablastic plasmacytomas from NFS.V(+) and SJL-beta2M(-/-) mice did not have structural alterations in Myc or T(12;15) translocations and did not express Myc at high levels, regular features of transgenic and pristane-induced plasmacytomas. "
|7.||Thalidomide (Thalomid)FDA Link
05/01/2006 - "We first recognized the lack of efficacy of thalidomide in soft-tissue plasmacytomas. "
07/01/2004 - "However, the efficacy of thalidomide in patients with soft-tissue plasmacytomas is controversial. "
08/01/2001 - "The second patient was treated with thalidomide for resistant MM. Despite a medullary response he developed neurological signs compatible with cranial nerve involvement and an MRI study was suggestive of a plasmacytoma involving the sellar region. "
11/01/2014 - "We report a rare case of a gastric plasmacytoma treated with endoscopic resection and oral thalidomide therapy. "
11/01/2014 - "Successful treatment of a gastric plasmacytoma using a combination of endoscopic submucosal dissection and oral thalidomide."
|8.||Dexamethasone (Maxidex)FDA LinkGeneric
06/01/2015 - "We report a case of plasmacytoma within the medial rectus muscle, which regressed completely with localized infiltration of dexamethasone. "
06/01/2015 - "Isolated extraocular muscle infiltration with plasmacytoma treated with localized injection of dexamethasone."
11/01/1992 - "The effects of dexamethasone, dibutyric-(DB)-cAMP and phorbol-12-myristate-13-acetate (TPA) have been studied on plasmacytoma cell line U266, B cell line BMNH and monocytoid cell line U937. "
11/01/2010 - "High-dose dexamethasone was added to the IM therapy because the patient refused radiotherapy to control the aggravated pulmonary plasmacytoma. "
01/01/2011 - "A 42-year-old man with prolonged dexamethasone use because of recurred plasmacytoma developed fever and tender red swelling of the right upper leg and arm. "
|9.||Interleukin-6 (Interleukin 6)IBA
07/01/1995 - "Much of the evidence supporting this suggestion is derived from in vitro studies in which the survival or proliferation of some plasma cell tumors has been found to be IL-6 dependent. "
01/01/2015 - "The tumor microenvironment is the main source of IL-6 for plasma cell tumor development in mice."
08/12/2011 - "We demonstrated that ectopic expression of K13, but not its NF-κB-defective mutant or a structural homolog, protected plasmacytomas against IL6 withdrawal-induced apoptosis and resulted in emergence of IL6-independent clones that could proliferate long-term in vitro in the absence of IL6 and form abdominal plasmacytomas with visceral involvement when injected intraperitoneally into syngeneic mice. "
08/12/2011 - "Because human herpesvirus 8-encoded K13 selectively activates the NF-κB pathway, we have used it as a molecular tool to examine the ability of the NF-κB pathway to confer IL6 independence on murine plasmacytomas. "
03/04/2010 - "IL-6 and MYC collaborate in plasma cell tumor formation in mice."
|10.||PC6 extract (PC6)IBA
08/01/1992 - "In vitro cytotoxicity and in vivo antitumor studies were carried out using the ADJ/PC6 plasmacytoma. "
01/01/1985 - "Activity has been shown in preclinical studies in mice bearing intraperitoneal P388 and L1210 leukaemias, ADJ-Pc6 plasmacytoma and a variety of solid tumours. "
01/01/1998 - "However, initial in vivo testing against a solid mouse plasmacytoma (PC6) and P388 leukaemia has not revealed significant activity."
07/01/1996 - "to ADJ/PC6 plasmacytoma bearing mice (ED90 of 1.0 and 0.4 versus 5.7 and 4.2 mg/kg, TI (therapeutic index) of 14 and 37 versus 5.3 and 4.2). "
01/01/1996 - "Antitumour activity was assessed in the bifunctional alkylating-agent-sensitive murine plasmacytoma ADJ/PC6 using a variety of administration protocols. "
06/01/2012 - "Complete remission of localised gastric plasmacytomas following definitive radiotherapy."
07/01/2006 - "The gold standard of treatment for plasmocytoma is its total removal and adjuvant radiation therapy; however, there is evidence for good results when it is partially removed and undergoes radiotherapy or after radical surgery without subsequent radiation. "
06/01/1989 - "This review of 84 cases of solitary plasmacytoma of the spine confirms the significantly greater survival of patients with solitary plasmacytoma, and supports the use of radiotherapy as the treatment modality of choice."
05/01/1997 - "Radiotherapy appears to be an effective modality of treatment of solitary plasmacytoma. "
01/01/2015 - "Radiotherapy Alone is Associated with Improved Outcomes Over Surgery in the Management of Solitary Plasmacytoma."
|2.||Drug Therapy (Chemotherapy)
10/01/2009 - "A 66 year-old woman was diagnosed of a cranial base solitary plasmacytoma and treated with radio and chemotherapy with complete remission. "
04/29/2014 - "The DECP chemotherapy is both effective and safe in the treatment of relapsed and refractory MM patients with extramedullary plasmacytomas."
09/01/1996 - "Previous research in our laboratories has shown that the immunoregulatory octapeptide, THF-gamma 2, potentiates the efficacy of anticancer chemotherapy in experimental animal models of local plasmacytoma and repairs drug-induced defects in immunocompetence. "
04/01/1993 - "After chemotherapy the dermatological lesions improved rapidly, and the plasmocytoma reached remission stage. "
06/01/1985 - "Indeed, when positive results are obtained by this method in visceral localizations of plasmacytoma, hazardous surgery may be avoided and radiation and/or chemotherapy may be chosen preferentially."
06/01/1998 - "Graft-versus-myeloma after donor leukocyte infusion: maintenance of marrow remission but extramedullary relapse with plasmacytomas."
02/01/2014 - "Three years after the first transplant a single peritoneal mass was detected on surveillance imaging and radically excised; HLA phenotyping confirmed the mass to be an isolated extra-medullary plasmacytoma of chimeric donor and recipient origin. "
02/01/2014 - "We describe a liver transplant from a donor with unrecognized plasmacytoma requiring retransplantation. "
02/21/2013 - "Plasma cell tumors in transplant patients."
07/01/2010 - "Disease recurrence in a transplant kidney in a patient with extramedullary plasmacytoma."
|4.||Combination Drug Therapy (Combination Chemotherapy)
01/01/1986 - "Polychemotherapy has improved prognostic parameters of survival in patients with plasmocytoma. "
12/01/2001 - "The purpose of this study is to report an extremely rare case of solitary bone plasmacytoma with a mandibular localization treated with radio- and polychemotherapy."
04/01/1993 - "In our patient, this was possible for the pancreatic plasmocytoma, whereas the hepatic lesion was first treated with general polychemotherapy because of the tumour size and adverse prognostic factors. "
10/01/1991 - "Therefore polychemotherapy was given, during which complete macroscopic and microscopic regression of the laryngeal plasmacytoma was observed. "
11/01/1999 - "The patient developed malignant lymphoma (small, non-cleaved cell, and non Burkitt's type by Working Formulation classification), and remained in remission for 2 years after receiving combination chemotherapy, and then developed plasmacytoma in the same lesion. "
04/01/2004 - "- To describe natural history of solitary bone plasmocytomas (SBO) after treatment. "
09/01/1997 - "These cases appeared to have a better prognosis than other extramedullary plasmacytomas, with rare recurrence and no progression to myeloma after treatment. "
01/01/1991 - "syndrome with complete recovery after treatment of a solitary plasmocytoma."
01/01/1988 - "Some T cell-dependent immune parameters were examined in mice bearing a large MOPC-315 plasmacytoma before and after treatment with a low dose (15 mg/kg) of CY. "
05/01/1998 - "This group included eight with monoclonal gammopathy of undetermined significance (MGUS), five with plasmacytoma (PCM), nineteen with multiple myeloma (MM; six newly diagnosed, seven plateau, five refractory, one relapse) and eleven amyloidosis (seven newly diagnosed, four after treatment). "